Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference
Rhea-AI Summary
Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotechnology company focused on developing transformative medicines for immune and inflammatory diseases, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference in New York.
The company's Co-Founder and CEO, Sandeep Kulkarni, MD, will participate in a fireside chat scheduled for Wednesday, February 5, 2025, at 1:30 pm ET. Investors and interested parties can access both the live webcast and replay of the presentation through the 'Events and Presentations' section on Tourmaline Bio's investor relations website at ir.tourmalinebio.com.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, TRML declined 3.08%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference:
Guggenheim Securities SMID Cap Biotech Conference, New York
Fireside Chat
Wednesday, February 5, 2025, at 1:30 pm ET
A live webcast and replay, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at ir.tourmalinebio.com.
About Tourmaline Bio
Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006). For more information about Tourmaline Bio and pacibekitug, please visit https://www.tourmalinebio.com or follow us on LinkedIn or X.
Media Contact
Scient PR
Sarah Mishek
SMishek@ScientPR.com
Investor Contact
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com
FAQ
When is Tourmaline Bio (TRML) presenting at the Guggenheim Securities SMID Cap Biotech Conference?
How can investors watch Tourmaline Bio's (TRML) Guggenheim Securities conference presentation?
What type of diseases does Tourmaline Bio (TRML) focus on treating?
What is the format of Tourmaline Bio's (TRML) presentation at the Guggenheim conference?
